Rank
7
Vertex Pharmaceuticals
CAMBRIDGE, MA - FEBRUARY 8: Eric Olson, Vice President of the Cystic Fibrosis Franchise at Vertex Pharmaceuticals, holds a Kalydeco pill, at his office in Cambridge, Mass. on Wednesday, February 8, 2012. Kalydeco is a medication for Cystic Fibrosis. (Photo by Yoon S. Byun/The Boston Globe via Getty Images)Yoon S. Byun—The Boston Globe/Getty Images
Vertex got its start making a hepatitis C drug, but it has more recently homed in on medicine that treats symptoms of cystic fibrosis, a genetic disease that afflicts 75,000 people worldwide. Its two bestselling drugs, Orkambi and Kalydeco, account for 87% of its $2.6 billion in revenue. And in February, Vertex received approval of a third CF drug, Symdeko, which earned $186 million in its first quarter on the market—more than twice what analysts expected. The success of the drugs has helped Vertex more than double its revenue in three years.
Company Information
| Overall Score | 5 |
| Sector | Health Care |
| Industry | Biotechnology |
| CEO | Jeffrey M. Leiden |
| Website | www.vrtx.com |
| Employees | 2,300 |
| HQ Location | Boston |
| Revenues ($M) (Past 12 Months) | $2,623 |
| Profits ($M) (Past 12 Months) | $415 |
| Market Value as of Oct. 10, 2018 ($M) | $45,088 |